186 related articles for article (PubMed ID: 30787595)
1. The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies.
Wang T; Yu J; Liu M; Chen Y; Zhu C; Lu L; Wang M; Min L; Liu X; Zhang X; Gubat JA; Chen Y
Drug Des Devel Ther; 2019; 13():539-553. PubMed ID: 30787595
[TBL] [Abstract][Full Text] [Related]
2. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Shirakawa T; Kato K; Nagashima K; Nishikawa A; Sawada R; Takahashi N; Shoji H; Sasaki Y; Honma Y; Iwasa S; Takashima A; Okita N; Hamaguchi T; Yamada Y; Shimada Y
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1207-15. PubMed ID: 25267597
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma.
Li Y; Ji Y; Shen L; Yin X; Huang T; Deng B; Guo H; Wu Y; Chen Y
Front Oncol; 2022; 12():1015302. PubMed ID: 36605427
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis.
Zhao Y; Song R; Jia Y; Zhang X; Zhang S; Wu C; Zhang R; Guo Z
Curr Oncol; 2022 Sep; 29(9):6610-6627. PubMed ID: 36135088
[TBL] [Abstract][Full Text] [Related]
5. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.
Pandy JGP; Balolong-Garcia JC; Cruz-Ordinario MVB; Que FVF
BMC Cancer; 2019 Nov; 19(1):1065. PubMed ID: 31703646
[TBL] [Abstract][Full Text] [Related]
6. Cervical non-squamous carcinoma: an effective combination chemotherapy of taxane, anthracycline and platinum for advanced or recurrent cases.
Kimura T; Miyatake T; Ueda Y; Ohta Y; Enomoto T; Kimura T; Kamiura S
Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):200-4. PubMed ID: 22770633
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review.
Xu J; Bai Y; Li E; Xu N; Shi D; Qian J
Expert Rev Anticancer Ther; 2022 Sep; 22(9):981-998. PubMed ID: 35950848
[TBL] [Abstract][Full Text] [Related]
8. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
[TBL] [Abstract][Full Text] [Related]
9. Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.
Sonpavde G; Pond GR; Di Lorenzo G; Buonerba C; Rozzi A; Lanzetta G; Necchi A; Giannatempo P; Raggi D; Matsumoto K; Choueiri TK; Mullane S; Niegisch G; Albers P; Lee JL; Kitamura H; Kume H; Bellmunt J
Clin Genitourin Cancer; 2016 Dec; 14(6):494-498. PubMed ID: 27262369
[TBL] [Abstract][Full Text] [Related]
10. Real-world outcomes with second-line therapy in advanced esophageal squamous cell carcinoma using SEER-Medicare data.
Danese M; Gricar J; Abraham P
Future Oncol; 2022 Mar; 18(8):927-936. PubMed ID: 35081734
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Thuss-Patience PC; Shah MA; Ohtsu A; Van Cutsem E; Ajani JA; Castro H; Mansoor W; Chung HC; Bodoky G; Shitara K; Phillips GDL; van der Horst T; Harle-Yge ML; Althaus BL; Kang YK
Lancet Oncol; 2017 May; 18(5):640-653. PubMed ID: 28343975
[TBL] [Abstract][Full Text] [Related]
12. Analysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancer.
Boggs DH; Tarabolous C; Morris CG; Hanna A; Burrows W; Horiba N; Suntharalingam M
Dis Esophagus; 2015 Oct; 28(7):619-25. PubMed ID: 24863682
[TBL] [Abstract][Full Text] [Related]
13. Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients.
Lopez A; Harada K; Chen HC; Bhutani MS; Weston B; Lee JH; Maru DM; Chin FW; Rogers JE; Thomas I; Amlashi FG; Blum-Murphy MA; Rice DC; Zhao M; Hofstetter WL; Nguyen Q; Ajani JA
Medicine (Baltimore); 2020 Feb; 99(9):e19295. PubMed ID: 32118743
[TBL] [Abstract][Full Text] [Related]
14. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
[TBL] [Abstract][Full Text] [Related]
15. Taxane-containing regimens for metastatic breast cancer.
Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Ter Veer E; Haj Mohammad N; van Valkenhoef G; Ngai LL; Mali RMA; Anderegg MC; van Oijen MGH; van Laarhoven HWM
J Natl Cancer Inst; 2016 Oct; 108(10):. PubMed ID: 27576566
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study.
Ohnuma H; Sato Y; Hayasaka N; Matsuno T; Fujita C; Sato M; Osuga T; Hirakawa M; Miyanishi K; Sagawa T; Fujikawa K; Ohi M; Okagawa Y; Tsuji Y; Hirayama M; Ito T; Nobuoka T; Takemasa I; Kobune M; Kato J
Cancer Sci; 2018 Nov; 109(11):3554-3563. PubMed ID: 30137686
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab in combination with different platinum-based doublets in the first-line treatment for advanced nonsquamous non-small-cell lung cancer: A network meta-analysis.
Zhao S; Gao F; Zhang Y; Zhang Z; Zhang L
Int J Cancer; 2018 Apr; 142(8):1676-1688. PubMed ID: 29171009
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of radiotherapy or chemoradiotherapy after taxane-based induction chemotherapy for nonoperated locally advanced head and neck squamous cell carcinomas.
Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Daly-Schveitzer N; Bourhis J; Tao Y
Anticancer Drugs; 2014 Nov; 25(10):1220-6. PubMed ID: 25144345
[TBL] [Abstract][Full Text] [Related]
20. Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer: Survival and Response to Treatment.
Aydiner A; Sen F; Tambas M; Ciftci R; Eralp Y; Saip P; Karanlik H; Fayda M; Kucucuk S; Onder S; Yavuz E; Muslumanoglu M; Igci A
Medicine (Baltimore); 2015 Dec; 94(52):e2341. PubMed ID: 26717372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]